Search Results - Vosganian, Gregory

  • Showing 1 - 12 results of 12
Refine Results
  1. 1
    First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

    First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma by Italiano, Antoine, Cassier, Philippe A., Lin, Chia-Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her-Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    PB2198: TRIAL IN PROGRESS: AN OPEN‐LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL‐895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

    PB2198: TRIAL IN PROGRESS: AN OPEN‐LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL‐895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS)... by Palandri, Francesca, Gröpper, Stefanie, Loschi, Michael, Bellesso, Marcelo, Grosicki, Sebastian, Giraldo, Pilar, Harrison, Claire, Clevenger, Tracy, Stuart, Nikki, Qamoos, Hope, Vosganian, Gregory, Rothbaum, Wayne P., Verstovsek, Srdan, Vachhani, Pankit

    Published in HemaSphere
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

    Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181) by Powderly, John, Spira, Alexander, Kondo, Shunsuke, Doi, Toshihiko, Luke, Jason J., Rasco, Drew, Gao, Bo, Tanner, Minna, Cassier, Philippe A., Gazzah, Anas, Italiano, Antoine, Tosi, Diego, Afar, Daniel E., Parikh, Apurvasena, Engelhardt, Benjamin, Englert, Stefan, Lambert, Stacie L., Kasichayanula, Sreeneeranj, Mensing, Sven, Menon, Rajeev, Vosganian, Gregory, Tolcher, Anthony

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer

    Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer by Calvo, Emiliano, Spira, Alexander, Miguel, María de, Kondo, Shunsuke, Gazzah, Anas, Millward, Michael, Prenen, Hans, Rottey, Sylvie, Warburton, Lydia, Alanko, Tuomo, Cassier, Philippe A., Yoh, Kiyotaka, Italiano, Antoine, Moreno, Victor, Peltola, Katriina, Seto, Takashi, Toyozawa, Ryo, Afar, Daniel E., Englert, Stefan, Komarnitsky, Philip, Lambert, Stacie, Parikh, Apurvasena, Vosganian, Gregory, Gao, Bo

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Effects of long-term cryopreservation on peripheral blood progenitor cells

    Effects of long-term cryopreservation on peripheral blood progenitor cells by Vosganian, Gregory S, Waalen, Jill, Kim, Kevin, Jhatakia, Sejal, Schram, Ethan, Lee, Tracey, Riddell, Dan, Mason, James R

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Primary intraocular lymphoma: a review

    Primary intraocular lymphoma: a review by Vosganian, Gregory S., Boisot, Saskia, Hartmann, Kathrin I., Freeman, William R., Sharpe, Robert W., Tripuraneni, Prabhakar, Saven, Alan

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Abstract 4464: Pharmacodynamic and predictive biomarkers of clinical responses to PD-1 inhibitor budigalimab from the first-in-human clinical trial

    Abstract 4464: Pharmacodynamic and predictive biomarkers of clinical responses to PD-1 inhibitor budigalimab from the first-in-human clinical trial by Lambert, Stacie, Zhang, Chun, Englert, Stefan, Guo, Claire, Turan, Tolga, Tribouley, Catherine, Masica, David, McLaughlin, Robert T., Vosganian, Gregory S., Afar, Daniel E.

    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors

    Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors by Powderly, John, Shimizu, Toshio, LoRusso, Patricia, Razak, Albiruni, Miller, Kathy, Balar, Arjun, Bruix, Jordi, Michel, Loren, Blaney, Martha, Guan, Xiaowen, Lacy, Susan, Lally, Satwant, Lambert, Stacie, Leibman, Rachel, Vosganian, Gregory, Golan, Talia, Tolcher, Anthony

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    Immunologic Effects of An Oral BRAF Inhibitor in a BRAF Wild-Type Murine Model

    Immunologic Effects of An Oral BRAF Inhibitor in a BRAF Wild-Type Murine Model by Vosganian, Gregory S., Bos, Rinke, Sherman, Linda

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

    Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - R... by Flinn, Ian W., Brunvand, Mark, Choi, Michael Y., Dyer, Martin J.S., Gribben, John, Hillmen, Peter, Jones, Jeffrey, Li, Yan, Mobasher, Mehrdad, Vosganian, Gregory, Kipps, Thomas J.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  11. 11
    Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

    Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leu... by Flinn, Ian, Brunvand, Mark, Dyer, Martin JS, Hillman, Peter, Jones, Jeffrey, Lymp, James, Elhamy, Mostafa, Vosganian, Gregory, Huang, Jane, Kipps, Thomas J.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  12. 12
    Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

    Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymp... by Salles, Gilles Andre, Boyd, Thomas E, Morschhauser, Franck, Wendtner, Clemens-Martin, Lymp, James, Hilger, James, Vosganian, Gregory, Huang, Jane, Stilgenbauer, Stephan

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: